Registry of prospective clinical trials second report.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects; D004176:Dipyridamole / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D007390:International Agencies; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000494:pharmacology; D012042:Registries; D013300:Streptokinase / Q000494:pharmacology; D013442:Sulfinpyrazone / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology; D014688:Venoms / Q000494:pharmacology
D005343:Fibrinolytic Agents; D006490:Hemostatics; D014688:Venoms; D004176:Dipyridamole; D010958:Plasminogen; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin; D013442:Sulfinpyrazone